|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.74 USD | +0.59% |
|
+2.90% | +25.14% |
| 07-22 | UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating | MT |
| 07-21 | Roche, Nurix Therapeutics Close Deal for Global Partnership for Bexobrutideg | MT |
| Market Cap | 2.46B 2.17B 2.01B 1.85B 3.47B 239B 3.53B 24.07B 9.39B 116B 9.25B 9.05B 404B | P/E 2026 * |
-8.63x | P/E 2027 * | -10.7x |
|---|---|---|---|---|---|
| Enterprise Value | 1.37B 1.2B 1.12B 1.03B 1.93B 132B 1.96B 13.36B 5.21B 64.61B 5.13B 5.02B 224B | EV / Sales 2026 * |
23.7x | EV / Sales 2027 * | 16x |
| Free-Float |
98.66% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nurix Therapeutics, Inc.
| 1 day | +0.59% | ||
| 1 week | +2.90% | ||
| Current month | -2.14% | ||
| 1 month | +25.87% | ||
| 3 months | +43.27% | ||
| 6 months | +27.91% | ||
| Current year | +25.14% |
| 1 week | 22.64 |  | 24.17 |
| 1 month | 19.34 | | 25.08 |
| Current year | 14.01 | | 25.08 |
| 1 year | 8.2 | | 25.08 |
| 3 years | 4.22 | | 29.56 |
| 5 years | 4.22 | | 37.42 |
| 10 years | 4.22 | | 52.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Arthur Sands
CEO | Chief Executive Officer | 64 | 2014-09-17 |
Hans van Houte
DFI | Director of Finance/CFO | 60 | 2016-02-29 |
Seema Rogers
CTO | Chief Tech/Sci/R&D Officer | - | 2019-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Arthur Sands
BRD | Director/Board Member | 64 | 2014-09-17 |
David Lacey
CHM | Chairman | 73 | 2019-07-31 |
Julia Gregory
CHM | Chairman | 72 | 2024-05-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/2/26 | Fiscal year | Compliance Officer | 33,024 | 0.0319% | ||
| 6/25/26 | Fiscal year | Compliance Officer | 86,805 | 0.0839% | ||
| 6/25/26 | Sell | Chief Technology Officer | -5,394 | 0.0052% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.59% | +2.90% | +104.13% | +135.75% | 2.45B | |
| +1.23% | +0.35% | +51.62% | +87.98% | 55.27B | |
| +5.09% | +6.24% | +63.15% | +62.06% | 54.15B | |
| +0.72% | -0.05% | +3.84% | +409.54% | 23.11B | |
| +0.25% | +0.55% | -19.67% | -15.22% | 23.22B | |
| -0.66% | +5.41% | +30.59% | -3.87% | 20.33B | |
| -0.37% | +0.71% | +31.36% | -31.61% | 17.91B | |
| -1.15% | +5.37% | +32.16% | +542.23% | 15.76B | |
| -2.54% | -8.73% | +164.11% | +289.45% | 15B | |
| +1.22% | -0.05% | +22.58% | +182.63% | 13.82B | |
| Average | +0.38% | +0.93% | +48.39% | +165.89% | 24.1B | |
| Weighted average by Cap. | +1.24% | +2.77% | +44.07% | +134.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.74M 50.78M 47.18M 43.39M 81.37M 5.59B 82.83M 564M 220M 2.73B 217M 212M 9.46B | 96.4M 84.78M 78.76M 72.44M 136M 9.34B 138M 942M 367M 4.55B 362M 354M 15.8B |
| Net income | -303M -267M -248M -228M -427M -29.34B -435M -2.96B -1.15B -14.31B -1.14B -1.11B -49.66B | -249M -219M -204M -187M -351M -24.13B -357M -2.43B -950M -11.77B -935M -915M -40.83B |
| Net Debt | -1.1B -964M -895M -824M -1.54B -106B -1.57B -10.71B -4.18B -51.77B -4.11B -4.03B -180B | -923M -811M -754M -693M -1.3B -89.35B -1.32B -9.01B -3.52B -43.58B -3.46B -3.39B -151B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-23 | US$23.74 | +0.59% | 965,869 |
| 26-07-22 | US$23.60 | +0.51% | 1,130,653 |
| 26-07-21 | US$23.48 | +3.39% | 961,277 |
| 26-07-20 | US$22.71 | -1.77% | 1,255,814 |
| 26-07-17 | US$23.12 | +0.22% | 794,891 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NRIX Stock
Select your edition
All financial news and data tailored to specific country editions
